ENZY News Alert Enzymotec Ltd (ENZY) 5.68 02/14/2015 00:29:5

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 1:30 AM

Enzymotec Ltd (ENZY) 5.68 $ENZY

Enzymotec Ltd. Announces the Appointment of Holger Liepmann to Its Board of Directors
GlobeNewswire - Fri Feb 13, 7:30AM CST
Enzymotec Ltd. (Nasdaq:ENZY) (the "Company"

, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the appointment of Holger Liepmann to its Board of Directors, effective February 12, 2015.
ENZY: 5.68 (-0.02)

Enzymotec reports February 18
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:11AM CST

ENZY: 5.68 (-0.02)

Enzymotec to Report Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Wed Feb 04, 7:30AM CST
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2014 on Wednesday, February 18, 2015, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer will host a conference call to review the financial results.
ENZY: 5.68 (-0.02)

Enzymotec Ltd. Announces Favorable Response From the Australian Patent Office
GlobeNewswire - Tue Feb 03, 8:01AM CST
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"

, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that the Australian Patent Office has issued a favorable response to the Company's request for re-examination of Neptune Technologies & Bioressources' ("Neptune"

patent as it relates to krill oil in Australia.
ENZY: 5.68 (-0.02)

Enzymotec Ltd. Initiates Clinical Study of Vayacog in Mild Cognitive Impairment
GlobeNewswire - Tue Jan 20, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today the initiation of a clinical study to evaluate the long term efficacy of Vayacog(R) in patients with Mild Cognitive Impairment ("MCI"

. Vayacog is a proprietary prescription medical food for the dietary management of lipid imbalances associated with early memory impairment. Vayacog provides phosphatidylserine enriched with DHA, a unique lipid composition essential for the management of key biochemical modifications underlying losses in brain function.
ENZY: 5.68 (-0.02)

Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders
GlobeNewswire - Fri Jan 02, 3:05PM CST
Enzymotec Ltd. (Nasdaq:ENZY) (the "Company"

today announced that it will hold an Extraordinary General Meeting of Shareholders on Thursday, February 12, 2015. The record date for shareholders entitled to vote at the meeting is Friday, January 9, 2015.
ENZY: 5.68 (-0.02)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST

RKT: 70.00 (+0.69), KOG: 6.56 (-0.39), MEAS: 86.00 (+0.01), HHC: 144.41 (+6.41), AET: 96.12 (-0.96), DLPH: 78.70 (+0.64), DLTR: 76.82 (+0.97), AEM: 32.61 (+0.10), AUXL: 36.47 (-0.06), DG: 68.82 (+1.23), ABBV: 58.05 (+1.00), DXM: 7.08 (-0.03), MNK: 115.01 (+2.51), ATHL: 58.40 (unch), NCQ: 0.56 (+0.03), COV: 106.71 (-1.36), AU: 12.33 (+0.36), MYL: 55.85 (+1.34), IAG: 2.23 (-0.08), FDO: 77.86 (+0.31), MGM: 21.46 (+0.22), GNW: 8.67 (+0.17), HIG: 41.27 (+0.19), NG: 3.96 (+0.03), EQIX: 227.70 (-0.04), HSH: 62.96 (unch), OAS: 16.84 (-0.03), PETM: 82.70 (+0.03), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), BPOP: 33.07 (+0.01), ENZY: 5.68 (-0.02), FCX: 20.29 (+0.82), GFI: 4.83 (-0.21), CZR: 10.78 (+0.18), CVC: 20.60 (+0.32), CIE: 8.90 (+0.20), CACQ: 7.72 (+0.12), AGN: 229.49 (+1.87), ECA: 14.07 (+0.37), FCH: 10.55 (+0.01), R: 93.92 (+0.41), DTV: 87.51 (-0.32), KMDA: 4.23 (+0.03), ANV: 0.97 (-0.03), MOVE: 20.95 (-0.03), BAC: 16.61 (-0.06), GRFS: 34.65 (+0.28), POST: 48.62 (-0.25), HCA: 68.54 (-0.48), RDN: 16.10 (-0.43), BEE: 13.16 (-0.23), CPWR: 10.35 (+0.01), GLD: 117.98 (+0.64), RLGY: 48.86 (+0.52), MTG: 9.18 (+0.07), HMHC: 19.98 (-0.09), CMCSA: 59.47 (+1.09), CBS: 59.83 (+2.06), BABA: 89.05 (+1.95)

Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:44AM CST
Enzymotec Ltd. (ENZY) was a big mover last session, as the company saw its shares surge 15% on the day.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), GWPH: 78.09 (+1.70), ENZY: 5.68 (-0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST

CADC: 5.50 (-0.22), ANV: 0.97 (-0.03), BONE: 3.09 (+0.09), WLH: 22.85 (-0.13), CLDX: 20.97 (+0.53), ENZY: 5.68 (-0.02), TGEN: 5.37 (+0.11), CHOP: 0.87 (-0.01), MSBF: 10.25 (+0.05), NVGN: 2.79 (+0.17), DWA: 20.72 (+0.34), WHX: 0.61 (+0.06), VYFC: 19.72 (+0.12), VGGL: 1.77 (-0.08), SNSS: 2.28 (+0.01), DNR: 8.66 (+0.39), MOBI: 4.20 (-0.01), VPCO: 1.02 (+0.01), FOLD: 8.36 (-0.11), ATEA: 1.76 (+0.01)

Enzymotec's (ENZY) CEO Dr. Ariel Katz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:50PM CST

ENZY: 5.68 (-0.02)

Enzymotec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:34AM CST

ENZY: 5.68 (-0.02)

Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results
GlobeNewswire - Thu Nov 13, 6:30AM CST
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported its financial results for the third quarter ended September 30, 2014.
ENZY: 5.68 (-0.02)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:30PM CST

KSS: 68.25 (-0.58), VTNR: 3.55 (+0.25), TYC: 43.19 (+0.27), SPH: 45.22 (+0.20), FLY: 13.97 (+0.11), ENZY: 5.68 (-0.02), RWLK: 17.40 (-0.77), WMT: 85.81 (-0.08), RSTI: 24.12 (+0.20), SBH: 33.10 (+0.28), HP: 69.58 (+3.62), GIB: 41.90 (+0.05), TDG: 208.62 (+1.96), CLFD: 13.57 (-0.03), HIMX: 8.04 (+0.28), VIAB: 68.98 (+1.27), MMS: 59.14 (+0.12)

Enzymotec Ltd. Initiates Clinical Study of Vayarin(R) in Adult ADHD
GlobeNewswire - Tue Nov 11, 7:38AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer, and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced the initiation of a clinical study to evaluate the efficacy of Vayarin(R) in adults with Attention Deficit Hyperactivity Disorder, or ADHD.
ENZY: 5.68 (-0.02)

Enzymotec to Report Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer will host a conference call to review the financial results.
ENZY: 5.68 (-0.02)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Enzymotec Ltd. and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
GlobeNewswire - Wed Oct 29, 11:17AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"

(NASDAQ:ENZY) that all purchasers of the Company's securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

, have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
ENZY: 5.68 (-0.02)

NOV. 4th DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Mon Oct 27, 2:45PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"

(Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 5.68 (-0.02)

Which Stocks Hurt Billionaire Portfolios the Most in 2014?
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the worst for 19 billionaires who made their money investing.
BID: 44.89 (-0.19), CBI: 38.69 (+0.83), MDR: 2.77 (+0.12), DLIA: 0.01 (unch), EOPN: 8.55 (-0.01), PGEM: 13.79 (+0.24), ENZY: 5.68 (-0.02), GNC: 48.11 (-0.55), AMCC: 5.21 (+0.06), HHC: 144.41 (+6.41), LL: 63.69 (+0.89), VLTC: 0.77 (-0.04), CZR: 10.78 (+0.18), SNSS: 2.28 (+0.01), TWER: 2.24 (+0.13), SHOS: 12.86 (+0.47), DRYS: 1.01 (+0.02), CREE: 37.51 (+0.08)

ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd. -- ENZY
GlobeNewswire - Sat Oct 25, 4:49PM CDT
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq:ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO"

on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

. This action is pending in the United States District Court for the District of New Jersey.
ENZY: 5.68 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

New Chapter Recovery Garners Key Accreditations

Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Nomada Fund Launches: A Game-Changer in New Media

Changing the Investment Game In a world where tech isn't the only kingmaker, distribution is the new play. Welcome the Nomada Fund, a fresh face on the investment scene that's swapping cash for exposure. Forget the traditional media-for-equity model that only old-timers still drool over—these guys are taking it up a notch with their new Distribution for Equity approach,...

U.S. Millionaire Surge: Market Waves or Mirage?

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

AI-Designed Antivirals: A Brave New World

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...